Skip to main content
argenx SE logo

argenx SE — Investor Relations & Filings

Ticker · 1AE ISIN · NL0010832176 LEI · 7245009C5FZE6G9ODQ71 BR Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2026-03-19 Annual Report
Country NL Netherlands
Listing BR 1AE

About argenx SE

https://www.argenx.com/?allow=1

argenx SE is a global immunology company that develops and commercializes antibody-based therapies for severe autoimmune diseases. Its lead product, efgartigimod, is a neonatal Fc receptor (FcRn) antagonist designed to reduce pathogenic Immunoglobulin G (IgG) antibodies. Efgartigimod is marketed as VYVGART and VYVGART Hytrulo for approved indications including generalized myasthenia gravis (gMG) and chronic inflammatory demyelinating polyneuropathy (CIDP). The company is investigating efgartigimod for several other autoimmune conditions. Its pipeline also includes other first-in-class candidates, such as empasiprubart, a C2 inhibitor for IgM-driven autoimmune diseases. argenx operates an antibody innovation platform, collaborating with academic partners to translate immunology research into therapeutic candidates.

Recent filings

Filing Released Lang Actions
argenx SE, Jaarlijkse financiële verslaggeving
Annual Report Classification · 100% confidence The document is explicitly titled 'argenx Annual Report 2025' and contains comprehensive sections typical of a full annual report, including a table of contents, shareholder letter, financial statements, and management discussion. It is not an announcement of a report, but the report itself, covering the fiscal year ended December 31, 2025. FY 2025
2026-03-19 English
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
AGM Information Classification · 95% confidence The document is a press release from argenx announcing that they will present new clinical trial data at the upcoming 2026 American Academy of Neurology (AAN) Annual Meeting. It details the specific studies, presentation titles, and authors, and includes standard safety information for their products. This is a typical corporate announcement regarding upcoming scientific/investor presentations, which falls under the category of an Investor Presentation or general regulatory announcement. Given the focus on upcoming data dissemination to the medical and investor community, it is best classified as an Investor Presentation (IP).
2026-03-06 English
argenx Reports Full Year 2025 Financial Results and Provides Fourth Quarter Business Update
Earnings Release Classification · 100% confidence The document is a comprehensive press release from argenx detailing their full-year 2025 financial results, including unaudited condensed consolidated statements of profit or loss, business updates, and strategic priorities. It is not a full 10-K annual report, but rather an initial announcement of financial results and business highlights, which fits the definition of an Earnings Release (ER). FY 2025
2026-02-26 English
argenx Announces Positive Topline Results from Phase 3 ADAPT OCULUS Trial of VYVGART in Ocular Myasthenia Gravis
Earnings Release Classification · 95% confidence The document is a press release from argenx announcing positive topline results from a Phase 3 clinical trial (ADAPT OCULUS). It details the study's primary endpoint, statistical significance, and future regulatory plans (sBLA submission). This type of announcement, which focuses on clinical trial outcomes and drug development progress, is classified as a Regulatory Filing (RNS) within the provided schema, as it does not fit into specific categories like Earnings Release (which would focus on financial results) or Investor Presentation. Q1 2026
2026-02-26 English
argenx to Present at TD Cowen 46th Annual Healthcare Conference
Regulatory Filings Classification · 95% confidence The document is a short announcement (under 5,000 characters) informing the public that a company executive will be presenting at an upcoming healthcare conference. It provides details on how to access the webcast but does not contain the presentation materials themselves. This fits the definition of a general regulatory announcement or a corporate event notification, which falls under the RNS (Regulatory Filings) category as a fallback for miscellaneous announcements that do not fit specific report types.
2026-02-23 English
argenx to Report Full Year 2025 Financial Results and Fourth Quarter Business Update on February 26, 2026
Report Publication Announcement Classification · 100% confidence The document is a short announcement (under 5,000 characters) notifying the public about an upcoming conference call to discuss financial results. It does not contain the financial results themselves, but rather serves as an invitation/announcement for the event. According to the 'Menu vs Meal' rule, this is classified as a Report Publication Announcement (RPA).
2026-02-19 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.